Published in Front Immunol on August 27, 2012
CD73 Expressed on γδ T Cells Shapes Their Regulatory Effect in Experimental Autoimmune Uveitis. PLoS One (2016) 1.44
Regulatory T cells and their roles in immune dysregulation and allergy. Immunol Res (2014) 0.94
Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiency. Blood (2016) 0.92
Genetics of allergy and allergic sensitization: common variants, rare mutations. Curr Opin Immunol (2015) 0.89
Clinical applications of gene therapy for primary immunodeficiencies. Hum Gene Ther (2015) 0.88
B-cell development and functions and therapeutic options in adenosine deaminase-deficient patients. J Allergy Clin Immunol (2014) 0.83
An A2B Adenosine Receptor Agonist Promotes Th17 Autoimmune Responses in Experimental Autoimmune Uveitis (EAU) via Dendritic Cell Activation. PLoS One (2015) 0.81
Raised serum adenosine deaminase level in nonobese type 2 diabetes mellitus. ScientificWorldJournal (2013) 0.79
Adenosine Deaminase Deficiency - More Than Just an Immunodeficiency. Front Immunol (2016) 0.78
Intracellular adenosine inhibits IgE-dependent degranulation of human skin mast cells. J Clin Immunol (2013) 0.78
Eosinophilia Associated with Disorders of Immune Deficiency or Immune Dysregulation. Immunol Allergy Clin North Am (2015) 0.78
Primary immunodeficiency update: Part II. Syndromes associated with mucocutaneous candidiasis and noninfectious cutaneous manifestations. J Am Acad Dermatol (2015) 0.77
Adenosine deaminase deficient severe combined immunodeficiency presenting as atypical haemolytic uraemic syndrome. J Clin Immunol (2015) 0.76
Regulation of Adenosine Deaminase on Induced Mouse Experimental Autoimmune Uveitis. J Immunol (2016) 0.76
A semiautomated framework for integrating expert knowledge into disease marker identification. Dis Markers (2013) 0.75
Pleural effusion adenosine deaminase: a candidate biomarker to discriminate between Gram-negative and Gram-positive bacterial infections of the pleural space. Clinics (Sao Paulo) (2016) 0.75
Mechanism-Based Strategies for the Management of Autoimmunity and Immune Dysregulation in Primary Immunodeficiencies. J Allergy Clin Immunol Pract (2016) 0.75
Relationship between serum adenosine deaminase levels and liver histology in autoimmune hepatitis. World J Gastroenterol (2017) 0.75
Late Onset Combined Immunodeficiency Presenting with Recurrent Pneumocystis jiroveci Pneumonia. Case Rep Med (2014) 0.75
Regulatory T cells and immune tolerance. Cell (2008) 18.77
Predominant autoantibody production by early human B cell precursors. Science (2003) 13.14
Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol (2005) 13.03
How regulatory T cells work. Nat Rev Immunol (2008) 11.66
Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med (2007) 10.00
Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med (2006) 9.68
Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest (2008) 9.42
Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity. Lancet (1972) 9.01
Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med (2009) 8.20
Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest (2008) 7.05
Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood (2007) 6.03
Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol (2006) 6.00
Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature (2009) 4.98
Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov (2008) 4.76
Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors. Annu Rev Immunol (2004) 4.28
Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968-99. Lancet (2003) 3.44
Antigen presentation in the thymus for positive selection and central tolerance induction. Nat Rev Immunol (2009) 3.13
Immune cell regulation by autocrine purinergic signalling. Nat Rev Immunol (2011) 2.94
Human severe combined immunodeficiency: genetic, phenotypic, and functional diversity in one hundred eight infants. J Pediatr (1997) 2.92
A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells. Blood (2007) 2.69
Role of A2a extracellular adenosine receptor-mediated signaling in adenosine-mediated inhibition of T-cell activation and expansion. Blood (1997) 2.67
Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J Biol Chem (1977) 2.65
Regulatory T cells under scrutiny. Nat Rev Immunol (2003) 2.64
Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapy. J Clin Invest (2007) 2.63
Adenosine and cAMP are potent inhibitors of the NF-kappa B pathway downstream of immunoreceptors. Eur J Immunol (2005) 2.46
Direct association of adenosine deaminase with a T cell activation antigen, CD26. Science (1993) 2.40
A2A adenosine receptor induction inhibits IFN-gamma production in murine CD4+ T cells. J Immunol (2005) 2.37
Severe combined immunodeficiency and adenosine deaminase deficiency. N Engl J Med (1975) 2.35
Balancing immunity and tolerance: deleting and tuning lymphocyte repertoires. Proc Natl Acad Sci U S A (1996) 2.34
Purinergic control of T cell activation by ATP released through pannexin-1 hemichannels. Sci Signal (2008) 2.27
The cardiac effects of adenosine. Prog Cardiovasc Dis (1989) 2.20
How does adenosine inhibit transmitter release? Trends Pharmacol Sci (1988) 2.20
Adenosine receptor subtypes: characterization and therapeutic regulation. Annu Rev Pharmacol Toxicol (1995) 2.19
Generation and accumulation of immunosuppressive adenosine by human CD4+CD25highFOXP3+ regulatory T cells. J Biol Chem (2009) 2.18
The PTPN22 allele encoding an R620W variant interferes with the removal of developing autoreactive B cells in humans. J Clin Invest (2011) 2.14
Long-term outcome after hematopoietic stem cell transplantation of a single-center cohort of 90 patients with severe combined immunodeficiency. Blood (2009) 2.03
B-cell tolerance checkpoints in health and autoimmunity. Curr Opin Immunol (2008) 1.99
Expansion of functionally immature transitional B cells is associated with human-immunodeficient states characterized by impaired humoral immunity. J Immunol (2006) 1.96
Bruton's tyrosine kinase is essential for human B cell tolerance. J Exp Med (2004) 1.94
Back to central tolerance. Immunity (2004) 1.88
Activation of Th1 and Tc1 cell adenosine A2A receptors directly inhibits IL-2 secretion in vitro and IL-2-driven expansion in vivo. Blood (2005) 1.84
IRAK-4- and MyD88-dependent pathways are essential for the removal of developing autoreactive B cells in humans. Immunity (2008) 1.83
Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction. Sci Transl Med (2011) 1.81
Outcome of hematopoietic stem cell transplantation for adenosine deaminase-deficient severe combined immunodeficiency. Blood (2012) 1.80
Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase. N Engl J Med (1987) 1.75
Death, autoantigen modifications, and tolerance. Arthritis Res (2000) 1.75
How I treat ADA deficiency. Blood (2009) 1.70
Endosomal TLR signaling is required for anti-nucleic acid and rheumatoid factor autoantibodies in lupus. Proc Natl Acad Sci U S A (2009) 1.70
Unique risk factors for insertional mutagenesis in a mouse model of XSCID gene therapy. Proc Natl Acad Sci U S A (2006) 1.67
Cognitive and behavioral abnormalities in adenosine deaminase deficient severe combined immunodeficiency. J Pediatr (2001) 1.67
B-cell self-tolerance in humans. Adv Immunol (2007) 1.65
Adenosine deaminase-deficient mice generated using a two-stage genetic engineering strategy exhibit a combined immunodeficiency. J Biol Chem (1998) 1.64
Autocrine regulation of T-cell activation by ATP release and P2X7 receptors. FASEB J (2009) 1.61
Activation of antigen-presenting cells by microbial products breaks self tolerance and induces autoimmune disease. J Clin Invest (2004) 1.57
Too much of a good thing: adenosine overload in adenosine-deaminase-deficient mice. Trends Pharmacol Sci (2003) 1.52
In vivo inactivation of erythrocyte S-adenosylhomocysteine hydrolase by 2'-deoxyadenosine in adenosine deaminase-deficient patients. J Clin Invest (1979) 1.47
The establishment of early B cell tolerance in humans: lessons from primary immunodeficiency diseases. Ann N Y Acad Sci (2011) 1.45
Autoimmunity following haematopoietic stem-cell transplantation. Best Pract Res Clin Haematol (2007) 1.44
Adenosine affects expression of membrane molecules, cytokine and chemokine release, and the T-cell stimulatory capacity of human dendritic cells. Blood (2002) 1.44
Cornerstone of peripheral tolerance: naturally occurring CD4+CD25+ regulatory T cells. Trends Immunol (2004) 1.42
Signalling crosstalk in B cells: managing worth and need. Nat Rev Immunol (2009) 1.41
Brief report: hepatic dysfunction as a complication of adenosine deaminase deficiency. N Engl J Med (1996) 1.40
The use of enzyme therapy to regulate the metabolic and phenotypic consequences of adenosine deaminase deficiency in mice. Differential impact on pulmonary and immunologic abnormalities. J Biol Chem (2000) 1.40
Long-term efficacy of enzyme replacement therapy for adenosine deaminase (ADA)-deficient severe combined immunodeficiency (SCID). Clin Immunol (2005) 1.40
Severe combined immunodeficiency. A model disease for molecular immunology and therapy. Immunol Rev (2005) 1.39
ATP inhibits the generation and function of regulatory T cells through the activation of purinergic P2X receptors. Sci Signal (2011) 1.38
Cyclic AMP-dependent protein kinase type I mediates the inhibitory effects of 3',5'-cyclic adenosine monophosphate on cell replication in human T lymphocytes. J Biol Chem (1992) 1.37
Antibody responses to bacteriophage phi X174 in patients with adenosine deaminase deficiency. Blood (1992) 1.34
Adenosine A2A receptor antagonists: blockade of adenosinergic effects and T regulatory cells. Br J Pharmacol (2008) 1.30
Cognitive and behavioral abnormalities in children after hematopoietic stem cell transplantation for severe congenital immunodeficiencies. Blood (2008) 1.29
Adenosine deaminase deficiency increases thymic apoptosis and causes defective T cell receptor signaling. J Clin Invest (2001) 1.28
Immune deficiency and autoimmunity. Autoimmun Rev (2003) 1.27
PEG-ADA replacement therapy for adenosine deaminase deficiency: an update after 8.5 years. Clin Immunol Immunopathol (1995) 1.27
A2A adenosine receptor may allow expansion of T cells lacking effector functions in extracellular adenosine-rich microenvironments. J Immunol (2009) 1.27
New insights into adenosine-receptor-mediated immunosuppression and the role of adenosine in causing the immunodeficiency associated with adenosine deaminase deficiency. Eur J Immunol (2005) 1.25
Murine leukemias with retroviral insertions at Lmo2 are predictive of the leukemias induced in SCID-X1 patients following retroviral gene therapy. PLoS Genet (2009) 1.19
Altered intracellular and extracellular signaling leads to impaired T-cell functions in ADA-SCID patients. Blood (2008) 1.19
Alterations in the adenosine metabolism and CD39/CD73 adenosinergic machinery cause loss of Treg cell function and autoimmunity in ADA-deficient SCID. Blood (2011) 1.19
Inefficient clearance of dying cells and autoreactivity. Curr Top Microbiol Immunol (2006) 1.16
Adenosine deaminase deficiency with late onset of recurrent infections: response to treatment with polyethylene glycol-modified adenosine deaminase. J Pediatr (1988) 1.16
Adenosine deaminase deficiency in adults. Blood (1997) 1.15
cAMP/CREB-mediated transcriptional regulation of ectonucleoside triphosphate diphosphohydrolase 1 (CD39) expression. J Biol Chem (2010) 1.11
The different extent of B and T cell immune reconstitution after hematopoietic stem cell transplantation and enzyme replacement therapies in SCID patients with adenosine deaminase deficiency. J Immunol (2010) 1.10
Donor T-cell alloreactivity against host thymic epithelium limits T-cell development after bone marrow transplantation. Blood (2007) 1.10
T lymphocyte ontogeny in adenosine deaminase-deficient severe combined immune deficiency after treatment with polyethylene glycol-modified adenosine deaminase. J Clin Invest (1993) 1.09
IgG antibody response to polyethylene glycol-modified adenosine deaminase in patients with adenosine deaminase deficiency. J Clin Invest (1992) 1.08
Genotoxicity of retroviral hematopoietic stem cell gene therapy. Expert Opin Biol Ther (2011) 1.08
Hypotensive effects of adenosine and adenosine triphosphate compared with sodium nitroprusside. Anesth Analg (1982) 1.07
Adenosine kinase inhibition promotes survival of fetal adenosine deaminase-deficient thymocytes by blocking dATP accumulation. J Clin Invest (2002) 1.07
Reduced thymic output, increased spontaneous apoptosis and oligoclonal B cells in polyethylene glycol-adenosine deaminase-treated patients. Eur J Immunol (2005) 1.07
Therapeutic applications for hematopoietic stem cell gene transfer. Nat Immunol (2002) 1.06
Patients with adenosine deaminase deficiency surviving after hematopoietic stem cell transplantation are at high risk of CNS complications. Blood (2006) 1.06
Defective B cell tolerance in adenosine deaminase deficiency is corrected by gene therapy. J Clin Invest (2012) 1.06
Primary immunodeficiencies (PIDs) presenting with cytopenias. Hematology Am Soc Hematol Educ Program (2009) 1.05
Tolerance and autoimmunity: lessons at the bedside of primary immunodeficiencies. Adv Immunol (2007) 1.04
ATP depletion as a consequence of adenosine deaminase inhibition in man. Proc Natl Acad Sci U S A (1980) 1.04
Ex vivo gene therapy with lentiviral vectors rescues adenosine deaminase (ADA)-deficient mice and corrects their immune and metabolic defects. Blood (2006) 1.04
Phenotypic perturbation of B cells in the Wiskott-Aldrich syndrome. Clin Exp Immunol (2005) 1.03
The extracellular versus intracellular mechanisms of inhibition of TCR-triggered activation in thymocytes by adenosine under conditions of inhibited adenosine deaminase. Int Immunol (1999) 1.02
Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med (2009) 8.20
Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science (2013) 5.34
Hot spots of retroviral integration in human CD34+ hematopoietic cells. Blood (2007) 2.79
Comprehensive genomic access to vector integration in clinical gene therapy. Nat Med (2009) 2.19
Recent advances in understanding the pathophysiology of Wiskott-Aldrich syndrome. Blood (2009) 1.89
Integration of retroviral vectors induces minor changes in the transcriptional activity of T cells from ADA-SCID patients treated with gene therapy. Blood (2009) 1.88
Immune reconstitution in ADA-SCID after PBL gene therapy and discontinuation of enzyme replacement. Nat Med (2002) 1.80
Outcome of hematopoietic stem cell transplantation for adenosine deaminase-deficient severe combined immunodeficiency. Blood (2012) 1.80
WASP regulates suppressor activity of human and murine CD4(+)CD25(+)FOXP3(+) natural regulatory T cells. J Exp Med (2007) 1.77
How I treat ADA deficiency. Blood (2009) 1.70
Wiskott-Aldrich syndrome protein regulates lipid raft dynamics during immunological synapse formation. Immunity (2002) 1.69
T-cell suicide gene therapy prompts thymic renewal in adults after hematopoietic stem cell transplantation. Blood (2012) 1.56
SAP controls the cytolytic activity of CD8+ T cells against EBV-infected cells. Blood (2005) 1.44
Defective Th1 cytokine gene transcription in CD4+ and CD8+ T cells from Wiskott-Aldrich syndrome patients. J Immunol (2006) 1.44
Integration profile of retroviral vector in gene therapy treated patients is cell-specific according to gene expression and chromatin conformation of target cell. EMBO Mol Med (2011) 1.39
Retroviral integrations in gene therapy trials. Mol Ther (2012) 1.34
Altered intracellular and extracellular signaling leads to impaired T-cell functions in ADA-SCID patients. Blood (2008) 1.19
Alterations in the adenosine metabolism and CD39/CD73 adenosinergic machinery cause loss of Treg cell function and autoimmunity in ADA-deficient SCID. Blood (2011) 1.19
Preclinical safety and efficacy of human CD34(+) cells transduced with lentiviral vector for the treatment of Wiskott-Aldrich syndrome. Mol Ther (2012) 1.18
Developmental expression of the T-box transcription factor T-bet/Tbx21 during mouse embryogenesis. Mech Dev (2002) 1.16
Evidence for long-term efficacy and safety of gene therapy for Wiskott-Aldrich syndrome in preclinical models. Mol Ther (2009) 1.15
Gene therapy for primary immunodeficiencies: Part 1. Curr Opin Immunol (2012) 1.10
Skewed T-cell receptor repertoire, decreased thymic output, and predominance of terminally differentiated T cells in ataxia telangiectasia. Blood (2002) 1.07
Defective B cell tolerance in adenosine deaminase deficiency is corrected by gene therapy. J Clin Invest (2012) 1.06
The Wiskott-Aldrich syndrome protein is required for iNKT cell maturation and function. J Exp Med (2009) 1.06
Lentiviral vector-mediated gene transfer in T cells from Wiskott-Aldrich syndrome patients leads to functional correction. Mol Ther (2004) 1.06
Insertion sites in engrafted cells cluster within a limited repertoire of genomic areas after gammaretroviral vector gene therapy. Mol Ther (2011) 1.04
Ex vivo gene therapy with lentiviral vectors rescues adenosine deaminase (ADA)-deficient mice and corrects their immune and metabolic defects. Blood (2006) 1.04
Efficacy of gene therapy for Wiskott-Aldrich syndrome using a WAS promoter/cDNA-containing lentiviral vector and nonlethal irradiation. Hum Gene Ther (2006) 1.03
Lentiviral-mediated gene therapy leads to improvement of B-cell functionality in a murine model of Wiskott-Aldrich syndrome. J Allergy Clin Immunol (2011) 1.03
ADA-deficient SCID is associated with a specific microenvironment and bone phenotype characterized by RANKL/OPG imbalance and osteoblast insufficiency. Blood (2009) 1.01
Wiskott-Aldrich syndrome protein-mediated actin dynamics control type-I interferon production in plasmacytoid dendritic cells. J Exp Med (2013) 1.00
Challenges in vector and trial design using retroviral vectors for long-term gene correction in hematopoietic stem cell gene therapy. Mol Ther (2012) 0.98
Update on gene therapy for adenosine deaminase-deficient severe combined immunodeficiency. Curr Opin Allergy Clin Immunol (2010) 0.98
Management options for adenosine deaminase deficiency; proceedings of the EBMT satellite workshop (Hamburg, March 2006). Clin Immunol (2007) 0.97
Human IL2RA null mutation mediates immunodeficiency with lymphoproliferation and autoimmunity. Clin Immunol (2013) 0.95
Innate-like effector differentiation of human invariant NKT cells driven by IL-7. J Immunol (2008) 0.94
New insights into the pathogenesis of adenosine deaminase-severe combined immunodeficiency and progress in gene therapy. Curr Opin Allergy Clin Immunol (2009) 0.93
Revertant T lymphocytes in a patient with Wiskott-Aldrich syndrome: analysis of function and distribution in lymphoid organs. J Allergy Clin Immunol (2010) 0.92
Immunodysregulation of HIV disease at bone marrow level. Autoimmun Rev (2005) 0.92
Lentiviral-mediated gene therapy restores B cell tolerance in Wiskott-Aldrich syndrome patients. J Clin Invest (2015) 0.88
Clinical applications of gene therapy for primary immunodeficiencies. Hum Gene Ther (2015) 0.88
Unpredictability of intravenous busulfan pharmacokinetics in children undergoing hematopoietic stem cell transplantation for advanced beta thalassemia: limited toxicity with a dose-adjustment policy. Biol Blood Marrow Transplant (2009) 0.88
Capillary electrophoresis in diagnosis and monitoring of adenosine deaminase deficiency. Clin Chem (2003) 0.86
Serratia marcescens osteomyelitis in a newborn with chronic granulomatous disease. Pediatr Infect Dis J (2013) 0.86
Burkitt's lymphoma in a patient with adenosine deaminase deficiency-severe combined immunodeficiency treated with polyethylene glycol-adenosine deaminase. J Pediatr (2007) 0.86
Mobilized blood CD34+ cells transduced and selected with a clinically applicable protocol reconstitute lymphopoiesis in SCID-Hu mice. Hum Gene Ther (2004) 0.85
Hematopoietic stem cell gene therapy for adenosine deaminase deficient-SCID. Immunol Res (2009) 0.83
IL-3 or IL-7 increases ex vivo gene transfer efficiency in ADA-SCID BM CD34+ cells while maintaining in vivo lymphoid potential. Mol Ther (2004) 0.82
Human CD26 expression in transgenic mice affects murine T-cell populations and modifies their subset distribution. Hum Immunol (2002) 0.82
Decreased apoptosis of bone marrow progenitor cells in HIV-1-infected patients during highly active antiretroviral therapy. AIDS (2004) 0.82
Gene therapy for adenosine deaminase deficiency. Immunol Allergy Clin North Am (2010) 0.80
Purine metabolism, immune reconstitution, and abdominal adipose tumor after gene therapy for adenosine deaminase deficiency. J Allergy Clin Immunol (2011) 0.80
Improvement of interleukin 2 production, clonogenic capability and restoration of stromal cell function in human immunodeficiency virus-type-1 patients after highly active antiretroviral therapy. Br J Haematol (2002) 0.79
In vivo T-cell dynamics during immune reconstitution after hematopoietic stem cell gene therapy in adenosine deaminase severe combined immune deficiency. J Allergy Clin Immunol (2011) 0.79
Molecular purging of multiple myeloma cells by ex-vivo culture and retroviral transduction of mobilized-blood CD34+ cells. J Transl Med (2007) 0.79
Role of reduced intensity conditioning in T-cell and B-cell immune reconstitution after HLA-identical bone marrow transplantation in ADA-SCID. Haematologica (2010) 0.79
Lentiviral vectors for the treatment of primary immunodeficiencies. J Inherit Metab Dis (2014) 0.79
Bone marrow clonogenic capability, cytokine production, and thymic output in patients with common variable immunodeficiency. J Immunol (2005) 0.79
Successful treatment with percutaneous transhepatic alcoholization of a liver abscess in a child with chronic granulomatous disease. Pediatr Infect Dis J (2011) 0.78
Progress in gene therapy for primary immunodeficiencies using lentiviral vectors. Curr Opin Allergy Clin Immunol (2014) 0.78
Etiology, clinical outcome, and laboratory features in children with neutropenia: analysis of 104 cases. Pediatr Allergy Immunol (2013) 0.77
HIV type 1 protease inhibitors enhance bone marrow progenitor cell activity in normal subjects and in HIV type 1-infected patients. AIDS Res Hum Retroviruses (2005) 0.77
HIV-1 envelope-dependent restriction of CXCR4-using viruses in child but not adult untransformed CD4+ T-lymphocyte lines. Blood (2012) 0.76
Early-onset monocyte-B-natural killer-dendritic cells' deficiency successfully treated with hematopoietic stem cell transplantation. J Allergy Clin Immunol (2011) 0.76
Chronic granulomatous disease presenting with salmonella brain abscesses. Pediatr Infect Dis J (2014) 0.75
Interleukin 7 production by bone marrow-derived stromal cells in HIV-1-infected patients during highly active antiretroviral therapy. AIDS (2002) 0.75
Efficient gene transfer into primitive hematopoietic progenitors using a bone marrow microenvironment cell line engineered to produce retroviral vectors. Haematologica (2004) 0.75
Corrigendum to "Evidence for Long-term Efficacy and Safety of Gene Therapy for Wiskott-Aldrich Syndrome in Preclinical Models". Mol Ther (2016) 0.75
Longitudinal Evaluation of Immune Reconstitution and B-cell Function After Hematopoietic Cell Transplantation for Primary Immunodeficiency. J Clin Immunol (2015) 0.75
Current understanding of the Wiskott-Aldrich syndrome and prospects for gene therapy. Expert Rev Clin Immunol (2007) 0.75
Clinical improvement and normalized Th1 cytokine profile in early and long-term interferon-alpha treatment in a suspected case of hyper-IgE syndrome. Pediatr Allergy Immunol (2008) 0.75